Alpha Clinical Research of Georgia LLC
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walton, Marie
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT06972459: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
01/27
08/27
NCT06993792: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Recruiting
3
1200
Europe, Japan, US, RoW
Orforglipron, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
01/27
08/27
NCT06972472: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
01/27
08/27
GBT021601-021, NCT05431088: A Phase 2/3 Study in Adult and Pediatric Participants With SCD

Active, not recruiting
2/3
429
US, RoW
Osivelotor, PF-07940367 or GBT021601
Pfizer, Pfizer
Sickle Cell Disease
12/30
12/32
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Completed
2
354
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walton, Marie
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT06972459: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
01/27
08/27
NCT06993792: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Recruiting
3
1200
Europe, Japan, US, RoW
Orforglipron, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
01/27
08/27
NCT06972472: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
01/27
08/27
GBT021601-021, NCT05431088: A Phase 2/3 Study in Adult and Pediatric Participants With SCD

Active, not recruiting
2/3
429
US, RoW
Osivelotor, PF-07940367 or GBT021601
Pfizer, Pfizer
Sickle Cell Disease
12/30
12/32
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

Completed
2
354
Europe, US, RoW
OG-6219, Placebo
Organon and Co, Iqvia Pty Ltd
Endometriosis
05/25
05/25

Download Options